[go: up one dir, main page]

WO2015066664A3 - Compositions and methods for administration of an enzyme to a subject's airway - Google Patents

Compositions and methods for administration of an enzyme to a subject's airway Download PDF

Info

Publication number
WO2015066664A3
WO2015066664A3 PCT/US2014/063784 US2014063784W WO2015066664A3 WO 2015066664 A3 WO2015066664 A3 WO 2015066664A3 US 2014063784 W US2014063784 W US 2014063784W WO 2015066664 A3 WO2015066664 A3 WO 2015066664A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
airway
subject
methods
enzyme
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2014/063784
Other languages
French (fr)
Other versions
WO2015066664A2 (en
Inventor
Robert O. Williams, Iii
Steven Idell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
University of Texas at Austin
Original Assignee
University of Texas System
University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53005414&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2015066664(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to EP14857307.4A priority Critical patent/EP3065705A4/en
Priority to AU2014341862A priority patent/AU2014341862A1/en
Priority to MX2016005720A priority patent/MX2016005720A/en
Priority to JP2016552448A priority patent/JP2016535782A/en
Priority to US15/034,019 priority patent/US20160279209A1/en
Application filed by University of Texas System, University of Texas at Austin filed Critical University of Texas System
Priority to CN201480060878.2A priority patent/CN105764488A/en
Priority to KR1020167012122A priority patent/KR20160078986A/en
Priority to CA2928759A priority patent/CA2928759A1/en
Publication of WO2015066664A2 publication Critical patent/WO2015066664A2/en
Publication of WO2015066664A3 publication Critical patent/WO2015066664A3/en
Anticipated expiration legal-status Critical
Priority to US16/259,112 priority patent/US11033611B2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21068—Tissue plasminogen activator (3.4.21.68), i.e. tPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21073—Serine endopeptidases (3.4.21) u-Plasminogen activator (3.4.21.73), i.e. urokinase

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Methods and composition for delivery of enzymes to a subject's airway. In some aspects, nebulized composition of enzymes, such as plasminogen activators are provided. In further aspects perfluorocarbon compositions comprising enzymes, such as plasminogen activators are provided. Compositions may, in some aspects, be used for the treatment of lung infections or acute lung injury, such as inhalational smoke induced acute lung injury (ISALI).
PCT/US2014/063784 2013-11-04 2014-11-04 Compositions and methods for administration of an enzyme to a subject's airway Ceased WO2015066664A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
CA2928759A CA2928759A1 (en) 2013-11-04 2014-11-04 Compositions and methods for administration of an enzyme to a subject's airway
KR1020167012122A KR20160078986A (en) 2013-11-04 2014-11-04 Compositions and methods for administration of an enzyme to a subject's airway
MX2016005720A MX2016005720A (en) 2013-11-04 2014-11-04 Compositions and methods for administration of an enzyme to a subject's airway.
JP2016552448A JP2016535782A (en) 2013-11-04 2014-11-04 Compositions and methods for administration of enzymes to the respiratory tract of a subject
US15/034,019 US20160279209A1 (en) 2013-11-04 2014-11-04 Compositions and methods for administration of an enzyme to a subject's airway
EP14857307.4A EP3065705A4 (en) 2013-11-04 2014-11-04 Compositions and methods for administration of an enzyme to a subject's airway
CN201480060878.2A CN105764488A (en) 2013-11-04 2014-11-04 Compositions and methods for administration of enzyme to subject's airway
AU2014341862A AU2014341862A1 (en) 2013-11-04 2014-11-04 Compositions and methods for administration of an enzyme to a subject's airway
US16/259,112 US11033611B2 (en) 2013-11-04 2019-01-28 Compositions and methods for administration of an enzyme to a subject's airway

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361899739P 2013-11-04 2013-11-04
US61/899,739 2013-11-04

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US15/034,019 A-371-Of-International US20160279209A1 (en) 2013-11-04 2014-11-04 Compositions and methods for administration of an enzyme to a subject's airway
US16/259,112 Division US11033611B2 (en) 2013-11-04 2019-01-28 Compositions and methods for administration of an enzyme to a subject's airway

Publications (2)

Publication Number Publication Date
WO2015066664A2 WO2015066664A2 (en) 2015-05-07
WO2015066664A3 true WO2015066664A3 (en) 2015-09-17

Family

ID=53005414

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/063784 Ceased WO2015066664A2 (en) 2013-11-04 2014-11-04 Compositions and methods for administration of an enzyme to a subject's airway

Country Status (11)

Country Link
US (2) US20160279209A1 (en)
EP (1) EP3065705A4 (en)
JP (1) JP2016535782A (en)
KR (1) KR20160078986A (en)
CN (1) CN105764488A (en)
AU (1) AU2014341862A1 (en)
CA (1) CA2928759A1 (en)
CL (1) CL2016001062A1 (en)
MX (1) MX2016005720A (en)
PE (1) PE20160789A1 (en)
WO (1) WO2015066664A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102268883B1 (en) 2013-03-15 2021-06-28 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 Inhibition of Pulmonary Fibrosis with Nutlin-3a and Peptides
BR112021004404A2 (en) 2018-09-10 2021-08-03 Lung Therapeutics, Inc. fragments of modified peptides of the cav-1 protein and their use in the treatment of fibrosis
WO2021180068A1 (en) * 2020-03-09 2021-09-16 泰伦基国际有限公司 Method and drug for treating diseases caused by 2019 novel coronavirus

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4790305A (en) * 1986-06-23 1988-12-13 The Johns Hopkins University Medication delivery system
US5531219A (en) * 1994-11-04 1996-07-02 Alliance Pharmaceutical Corp. Use of liquid fluorocarbons to facilitate pulmonary drug delivery
US20030113271A1 (en) * 1997-01-29 2003-06-19 University Technology Corporation Formulations for pulmonary delivery
US20030219368A1 (en) * 2001-12-21 2003-11-27 Hammel Charles F. Pretreatment and regeneration of oxides of manganese
US20050036951A1 (en) * 2003-01-09 2005-02-17 Arizeke Pharmaceuticals, Inc. Methods of treating lung diseases
US20100183620A1 (en) * 2008-11-26 2010-07-22 Kaumudi Bhawe Compositions and methods for regulating collagen and smooth muscle actin expression by serpine2
US20130039847A1 (en) * 2009-06-30 2013-02-14 Justus-Liebig-Universitat Gieben Liposomes for pulmonary administration

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0266032A1 (en) 1986-08-29 1988-05-04 Beecham Group Plc Modified fibrinolytic enzyme
US5302390A (en) 1987-07-01 1994-04-12 Beecham Group Plc Hybrid proteins of human plasminogen and human t-PA, pharmaceutical compositions and methods of treatment
WO1998006426A1 (en) * 1996-08-14 1998-02-19 Gram Joergen Brodersen Use of a plasminogen activator for the treatment of pulmonary disorders
US20050169908A1 (en) 2004-01-23 2005-08-04 Kazunori Murakami Use of aerosolized antithrombin to treat acute lung injury
US20060198940A1 (en) 2005-03-04 2006-09-07 Mcmorrow David Method of producing particles utilizing a vibrating mesh nebulizer for coating a medical appliance, a system for producing particles, and a medical appliance
US20070157931A1 (en) 2005-07-11 2007-07-12 Richard Parker System and method for optimized delivery of an aerosol to the respiratory tract
CA2633099C (en) * 2005-12-21 2015-04-21 Uti Limited Partnership Treatment of respiratory diseases
SI22865A (en) 2008-09-25 2010-03-31 Univerza@V@Ljubljani Peptide uroaktivin as activator of enzyme urokinase
JP2014529614A (en) 2011-08-29 2014-11-13 トリフォイリウム・エピエス Compositions and methods for the treatment or prevention of pulmonary dysfunction induced by radiation or by chemotherapy

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4790305A (en) * 1986-06-23 1988-12-13 The Johns Hopkins University Medication delivery system
US5531219A (en) * 1994-11-04 1996-07-02 Alliance Pharmaceutical Corp. Use of liquid fluorocarbons to facilitate pulmonary drug delivery
US20030113271A1 (en) * 1997-01-29 2003-06-19 University Technology Corporation Formulations for pulmonary delivery
US20030219368A1 (en) * 2001-12-21 2003-11-27 Hammel Charles F. Pretreatment and regeneration of oxides of manganese
US20050036951A1 (en) * 2003-01-09 2005-02-17 Arizeke Pharmaceuticals, Inc. Methods of treating lung diseases
US20100183620A1 (en) * 2008-11-26 2010-07-22 Kaumudi Bhawe Compositions and methods for regulating collagen and smooth muscle actin expression by serpine2
US20130039847A1 (en) * 2009-06-30 2013-02-14 Justus-Liebig-Universitat Gieben Liposomes for pulmonary administration

Also Published As

Publication number Publication date
MX2016005720A (en) 2016-11-25
JP2016535782A (en) 2016-11-17
CA2928759A1 (en) 2015-05-07
PE20160789A1 (en) 2016-08-17
KR20160078986A (en) 2016-07-05
AU2014341862A1 (en) 2016-05-19
WO2015066664A2 (en) 2015-05-07
EP3065705A2 (en) 2016-09-14
US20190255157A1 (en) 2019-08-22
US20160279209A1 (en) 2016-09-29
CN105764488A (en) 2016-07-13
US11033611B2 (en) 2021-06-15
CL2016001062A1 (en) 2017-01-13
EP3065705A4 (en) 2017-10-18

Similar Documents

Publication Publication Date Title
EP3682875A3 (en) Methods of treating pediatric metabolic syndrome
PH12014502603A1 (en) D-amino acid compounds for liver disease
WO2015044782A3 (en) Intranasal dhe for the treatment of headache
WO2014205317A3 (en) Cyclic peptides as protein targeting agents
MX2009008617A (en) Use of il-23 antagonists for treatment of infection.
CL2012003723A1 (en) Compounds derived from 2-quinolinyl acetic acid; pharmaceutical composition; and use in the treatment of hiv and aids.
MX2012011222A (en) Compounds and pharmaceutical compositions for the treatment of viral infections.
WO2012088266A3 (en) Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
WO2012129084A3 (en) Glucosylceramide synthase inhibitors
EA033311B1 (en) Benzoxaborole derivatives as antibacterial agents
MX2021001169A (en) Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl] amino}acetic acid, compositions, and uses thereof.
IN2013MU03583A (en)
MX2013000369A (en) Treatment of lung infections by administration of tobramycin by aerolisation.
CL2014001437A1 (en) Compounds derived from aryl dihydropyridinone and piperidinone as inhibitors of monoacrylic glycerol acyltransferase (mgat2); pharmaceutical composition and combination; and use in the treatment and prevention of diabetes, hyperglycemia, retinopathy, metabolic syndrome, among other diseases.
WO2011160024A3 (en) Compounds useful as antiviral agents, compositions, and methods of use
WO2011141685A3 (en) Systemic nasal compositions comprising cocoyl proline or at least one of the constituents thereof
PH12014501937A1 (en) Pharmaceutical composition containing an antivirally active dihydroquinazoline derivative
WO2012051339A3 (en) Methods and compositions for treating respiratory conditions using platelet enriched plasma
SG10201804952QA (en) Glucosylceramide synthase inhibitors
WO2015056104A3 (en) Treatment of hepatic fibrosis using an inhibitor of cbp/catenin
BR112017018209A2 (en) therapeutic polypeptide products and uses thereof
WO2011002422A3 (en) Solubility enhancing pharmaceutical formulation
WO2016030899A8 (en) Methods of treating amyotrophic lateral scleroses
WO2015066664A3 (en) Compositions and methods for administration of an enzyme to a subject's airway
CA3011003A1 (en) Bacterial ghosts for the treatment of cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14857307

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2928759

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 000563-2016

Country of ref document: PE

ENP Entry into the national phase

Ref document number: 2016552448

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/A/2016/005720

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 15034019

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20167012122

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 16128893

Country of ref document: CO

ENP Entry into the national phase

Ref document number: 2014341862

Country of ref document: AU

Date of ref document: 20141104

Kind code of ref document: A

REEP Request for entry into the european phase

Ref document number: 2014857307

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2014857307

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14857307

Country of ref document: EP

Kind code of ref document: A2

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112016009746

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112016009746

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20160429